NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Status:
Completed
Trial end date:
2021-04-14
Target enrollment:
Participant gender:
Summary
This study will enroll and treat subjects with cutaneous neurofibromas with NFX-179, a
topical study drug. Eligible subjects will receive treatment for 28 days and be observed by a
study doctor for approximately 56 days. Subjects will be randomly assigned to 1 of 4
treatment groups. 3 of the treatment groups will receive a specific dose NFX-179, and 1 group
will receive placebo. The subject, study doctor, and NFlection Therapeutics will not know
what treatment group each subject is assigned. Study participation requires at least 7 clinic
visits, blood, urine, and tissue collection, images of the treated cutaneous neurofibromas,
electrocardiograms, and information regarding the subject's medical and disease history.